QBiotics Group Limited Collaborates with MSD

Pharma Tech Outlook: Pharma Tech Magazine

QBiotics Group Limited Collaborates with MSD

Pharma Tech Outlook | Wednesday, August 19, 2020

QBiotics Group Limited has announced its collaboration with MSD to improve unresectable melanoma treatment.

FREMONT, CA: QBiotics Group Limited (QGL) is a life sciences organization that develops novel anticancer and wound healing pharmaceuticals. The company is extremely pleased to announce that it has arrived at an agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA). Both the companies will evaluate the usage of lead molecule tigilanol tiglate by combining it with Keytruda(R) (pembrolizumab) in patients suffering from unresectable melanoma.

According to Dr. Victoria Gordon, Managing Director and CEO of QBiotics, "We are delighted to announce this collaboration with MSD. Patients with unresectable melanoma who have received prior checkpoint inhibitors currently have limited effective treatment options. Through this program we hope to see that when combined, tigilanol tiglate and Keytruda may produce additive anti-tumor immune responses and improve outcomes for patients."

The study of Phase I/II open-label 'QBC46-H06' is related to the dose-escalation and expansion with the principal objective of establishing the highest tolerated dose or the maximum achievable dose of the combination therapy. The secondary procedure for measurement consists of evaluating tumor responses in injected tumors and uninjected tumors, along with the efficiency of clinical factors. The patients who are suffering from unresectable melanoma and are exposed to immune checkpoint inhibitors are qualified to participate in the study.

Dr. Gordon continued, "This study follows on from encouraging Phase I data where tigilanol tiglate as a monotherapy showed a 27% treatment response rate, including an 18% complete response with full tumor destruction across a wide variety of solid tumor types (2). Two patients with melanoma that had complete responses also had an abscopal (anenestic) response. Melanoma is the second human application we are pursuing for tigilanol tiglate following on from our Phase I/II clinical trial in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) which commenced in December 2019".

Weekly Brief

Read Also